Evidence map›Paper›PMID 31468350›Full record

ArticleHead and neck pathology2020

SMARCB1 (INI-1)-Deficient Adenocarcinoma of the Sinonasal Tract: A Potentially Under-Recognized form of Sinonasal Adenocarcinoma with Occasional Yolk Sac Tumor-Like Features.

Akeesha A Shah, Deepali Jain, Emad Ababneh, Abbas Agaimy, Aaron P Hoschar, Christopher C Griffith, Kelly R Magliocca, Bruce M Wenig, Lisa M Rooper, Justin A Bishop

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Head and neck pathology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
7.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 70 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India · 2023
    Article
  10. Review
  11. [Sinonasal neoplasms: Update from the WHO 2022].Pathologie (Heidelberg, Germany) · 2023
    Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 7 institutions in 3 countries.

Akeesha A ShahDepartment of Pathology, Cleveland Clinic Foundation, Robert J. Tomsich Pathology and Laboratory Medicine Institute, 9500 Euclid Avenue/L25, Cleveland, OH, 44195, USA.
Deepali JainDepartment of Pathology, All India Institute of Medical Sciences, New Delhi, India.
Emad AbabnehDepartment of Pathology, Cleveland Clinic Foundation, Robert J. Tomsich Pathology and Laboratory Medicine Institute, 9500 Euclid Avenue/L25, Cleveland, OH, 44195, USA.
Abbas AgaimyInstitute of Pathology, University Hospital, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Erlangen, Germany.
Aaron P HoscharDepartment of Pathology, Cleveland Clinic Foundation, Robert J. Tomsich Pathology and Laboratory Medicine Institute, 9500 Euclid Avenue/L25, Cleveland, OH, 44195, USA.
Christopher C GriffithDepartment of Pathology, Cleveland Clinic Foundation, Robert J. Tomsich Pathology and Laboratory Medicine Institute, 9500 Euclid Avenue/L25, Cleveland, OH, 44195, USA.
Kelly R MaglioccaDepartment of Pathology and Laboratory Medicine, Emory University Hospital, Atlanta, GA, USA.
Bruce M WenigDepartment of Anatomic Pathology, Moffitt Cancer Center, Tampa, FL, USA.
Lisa M RooperDepartment of Pathology, The Johns Hopkins Hospital, Baltimore, MD, USA.
Justin A BishopDepartment of Pathology, University of Texas Southwestern Medical Center, Dallas, TX, USA. justin.bishop@utsouthwestern.edu.ORCID http://orcid.org/0000-0002-9743-4360
Cleveland Clinic · USAll India Institute of Medical Sciences · INEmory University Hospital · USFriedrich-Alexander-Universität Erlangen-Nürnberg · DEJohns Hopkins Hospital · USMoffitt Cancer Center · USSouthwestern Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The classification of sinonasal adenocarcinoma (SNAC) is complex. The high-grade, non-intestinal SNAC group is particularly heterogeneous, with tumors showing widely variable morphology. SMARCB1 (INI-1)-deficient sinonasal carcinoma is a newly described, aggressive tumor that usually resembles sinonasal undifferentiated carcinoma (SNUC) or non-keratinizing squamous cell carcinoma; however, glandular differentiation has been rarely reported and this feature may be under-recognized. We present a dedicated series of 12 SMARCB1-deficient SNACs. All tumors had an oncocytoid/plasmacytoid cytomorphology with variable degrees of glandular differentiation consisting of tubules and cribriform structures with foci of intracellular or intraluminal mucin. Three of 12 tumors exhibited foci of yolk sac tumor-like histologic features. The tumors were uniformly high-grade, with nuclear pleomorphism, elevated mitotic rates and frequent necrosis. By immunohistochemistry, all tumors were entirely SMARCB1-deficient, and 10 of 12 were CK7-positive. Occasional expression of CDX2 (4 of 12), CK20 (3 of 12), and p40 (3 of 10) was seen. Expression of yolk sac markers was variably present in tumors that harbored yolk sac-like areas but also tumors that did not: glypican-3 (10 of 11), SALL4 (6 of 11), HepPar-1 (4 of 11), PLAP (1 of 10), and AFP (1 of 11). SMARCB1-deficient sinonasal carcinoma, particularly the oncocytoid/plasmacytoid form, can demonstrate variable degrees of glandular differentiation. This unexpected morphology combined with variable immunohistochemical results may lead to misdiagnoses of high-grade intestinal or non-intestinal SNAC, myoepithelial carcinoma, or even yolk sac tumor or metastatic hepatocellular carcinoma.

Indexed as

AdenocarcinomaAdultAgedAged, 80 and overBiomarkers, TumorEndodermal Sinus TumorFemaleHumansMaleMiddle AgedParanasal SinusesParanasal Sinus NeoplasmsSMARCB1 ProteinYoung AdultBiomarkers, TumorSMARCB1 ProteinSMARCB1 protein, humanAdenocarcinomaINI-1SinonasalSMARCB1SMARCB1-deficient sinonasal carcinomaYolk sac tumor

Identifiers

PMID31468350
PMCPMC7235142
OpenAlexW2971075770

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.